Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • "Small Molecules" at AD

Current analyses of the pioneer among the JAK-i

    • Congress Reports
    • Dermatology and venereology
    • RX
    • Studies
  • 4 minute read

The first representative of the Janus kinase (JAK) inhibitor class to be approved for atopic dermatitis was baricitinib. In an extensive study program, this selective and reversible inhibitor of JAK-1 and JAK-2 has demonstrated rapid relief of itching and skin lesions – even in areas of the body that are often difficult to treat. Real-world data is now available that confirms this positive balance.

Pruritogenic cytokines that are involved in the pathogenesis of atopic dermatitis (AD) and trigger their cytokine response via the JAK-STAT signaling pathway are interleukin (IL)-4, IL-13 and IL-31 [1]. Upadacitinib and abrocitinib selectively inhibit JAK-1, whereas baricitinib has an equally high specificity for JAK-1 and -2 [2,3]. All three oral JAK inhibitors (JAK-i) are characterized by a rapid onset of action and often lead to a reduction in itching within a short period of time, as post-hoc analyses of the BREEZE study program on baricitinib show (box) [4–6].

Significant reduction in itching as early as week 2
In the BREEZE-AD1 and BREEZE-AD2 phase III trials, monotherapy with baricitinib and in BREEZE-AD7 a combination therapy of baricitinib with topical corticosteroids (TCS) was investigated [4,5]. Post-hoc analyses of pooled data from the BREEZE-AD1/AD2 studies show that a significantly higher proportion of study participants receiving baricitinib 4 mg daily (n=248) compared to placebo (n=493) achieved an NRS£ score of 0/1 at week 2 (8.9% vs. 1.6%; p<0.0001) and that these effects persisted or intensified up to week 16 (14.1% vs. 3.9%; p<0.0001) [6]. Even when combined with TCS, the differences between baricitinib 4 mg (n=111) vs. placebo (n=109) were already significant at week 2 (16.2% vs. 2.8%; p=0.0064) and this continued until week 16 (22.5% vs. 8.3%; p=0.0287) [6]. However, there is now also interesting new data on the question of how baricitinib performs in AD patients in everyday life, e.g. from registry studies and patient surveys.
£ NRS = numerical rating scale; 0=no itching, 10=worst imaginable itching

TREATgermany register study

TREATgermany is one of the largest AD registries with over 1600 patients currently included. In a recent analysis, data from 81 adult patients with moderate to severe AD who received baricitinib between October 2020 and August 2022 were evaluated [7]. The data from the initial examination and the three-month follow-up were analyzed with regard to various outcome parameters. The mean objective SCORAD** value changed from 45.9 at the beginning of the study to 28.2. In terms of EASI, the mean value decreased from 21.5 to 9.3. The EASI$-50 and EASI-75 rates rose to 60% and 44% respectively. Subjective symptoms, including itching and quality of life (DLQI&), also improved significantly. In summary, baricitinib showed good efficacy and tolerability in this interim analysis of the TREATgermany population. Data on long-term efficacy and safety are expected in the further course of the registry study. Compared to biologics, closer monitoring is required during therapy with JAK-i. Since Janus kinases mediate the effect of several inflammatory cytokines, JAK inhibition is associated with an increased risk of infection [1].

** SCORAD = SCORing Atopic Dermatitis (25-60 points=moderate; >60 points=severe; maximum score=103)
$ EASI = Eczema Area and Severity Index
& DLQI = Dermatology Life Quality Index

Multinational patient survey

A cross-national online questionnaire study investigated satisfaction with baricitinib therapy in patients with moderate to severe AD using a four-point Likert scale [8]. Adult AD patients who had been treated with baricitinib for ≥4 weeks in routine clinical practice in France (n=48), Germany (n=53) or the UK (n=69) were surveyed. The average age was 39.3 years, 59% were female and the mean time since AD diagnosis was 20.9 years. At the start of baricitinib therapy, at least 10% of the body surface was affected by AD in 28% and the mean pruritus NRS was 6.8 (SD 2.0), which corresponds to significant pruritus. 19% classified their AD as moderately severe, 79% as severe. After treatment with baricitinib, which lasted a median of 4 months (range: 1-24), the patients reported an improvement, with 56% stating that the AD was only mild or had almost disappeared. It was found that most patients were either satisfied (n=58; 34%) or very satisfied (n=53; 31%) with baricitinib therapy. High rates of ‘very satisfied’ and ‘satisfied’ were recorded for the control of AD, including a reduction in itching (36% and 56%), a reduction in pain in the skin area (26% and 51%) and an improvement in sleep quality (16% and 55%). 63% and 19% of patients stated that the pruritus had ‘greatly improved’ and ‘very greatly improved’ respectively since the start of treatment. This reflects the overall high level of patient satisfaction, particularly with regard to itching relief. This is a significant finding considering that one of the main goals of AD is to treat pruritus quickly and effectively.

Congress: Dermatologie kompakt praxisnah

Literature:

  1. Klein B, Treudler R, Simon JC: JAK-Inhibitoren in der Dermatologie – kleine Moleküle, grosse Wirkung? Übersicht über Wirkmechanismus, Studienergebnisse und mögliche unerwünschte Wirkungen. JDDG 2022; 20(1): 19-25.
  2. Bonnekoh H, Butze M, Metz M: Charakterisierung der Effekte von neuen Therapien zur Behandlung der atopischen Dermatitis auf den Pruritus. JDDG 2022; 20(2): 150-156.
  3. Nezamololama N, et al: Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib. Drugs Context. 2020 Nov 16;9:2020-8-5. doi: 10.7573/dic.2020-8-5.
  4. Simpson EL, et al: Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol 2020; 183(2): 242-255.
  5. Reich K, et al: Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 2020; 156(12): 1333-1343.
  6. Schlöbe A, et al: Minimal-To-No-Itch with Baricitinib in Patients With Moderate to Severe Atopic Dermatitis: Results From Three Randomized, Phase 3 Clinical Trials, P038. JDDG 2024; 22, Issue S1: 1-40.
  7. Traidl S, et al: Treatment of moderate-to-severe atopic dermatitis with baricitinib – results from an interim analysis of the TREATgermany registry, P024. JDDG 2024; 22, Issue S1: 1-40.
  8. Augustin M, et al: Treatment satisfaction of adult patients with moderate-to-severe atopic dermatitis treated with baricitinib in France, Germany, and the United Kingdom: final results from a cross-sectional patient survey, P039. JDDG 2024; 22, Issue S1: 1-40.

DERMATOLOGIE PRAXIS 2024; 34(3): 41 (published on 17.6.24, ahead of print)

Autoren
  • Mirjam Peter, M.Sc.
Publikation
  • DERMATOLOGIE PRAXIS
Related Topics
  • Atopic dermatitis
  • baricitinib
  • JAK-i
  • Real-World Data
  • small molecules
  • Special localizations
Previous Article
  • Atopic dermatitis and the skin microbiome

How does systemic therapy influence dysbiosis?

  • Congress Reports
  • Dermatology and venereology
  • RX
  • Studies
View Post
Next Article
  • Metabolic Dysfunction-Associated Steatotic Liver Disease

Cardiology and hepatology in one boat

  • Cardiology
  • Education
  • Endocrinology and Diabetology
  • Gastroenterology and Hepatology
  • General Internal Medicine
  • Pharmacology and toxicology
  • RX
  • Studies
View Post
You May Also Like
View Post
  • 12 min
  • Evidence, effectiveness and practical implications

Medicinal plants for allergic rhinitis

    • RX
    • Allergology and clinical immunology
    • Education
    • General Internal Medicine
    • ORL
    • Pharmaceutical medicine
    • Phytotherapy
    • Studies
View Post
  • 15 min
  • Current status and future prospects

Cell and gene therapies in modern cardiology

    • Cardiology
    • Education
    • Genetics
    • RX
    • Studies
View Post
  • 14 min
  • Patient-oriented recommendations for action

Effect of heat on diabetes technology

    • RX
    • CME continuing education
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Prevention and health care
    • Studies
View Post
  • 19 min
  • Cardiovascular risk and obesity

Pathomechanisms, secondary prevention and treatment options

    • RX
    • Cardiology
    • CME continuing education
    • Endocrinology and Diabetology
    • Nutrition
    • Sports Medicine
    • Studies
    • Training with partner
View Post
  • 6 min
  • Ventricular arrhythmias

Indication for ICD or WCD?

    • RX
    • Cardiology
    • Congress Reports
    • General Internal Medicine
    • Studies
View Post
  • 3 min
  • Early breast cancer

Overweight and obesity worsen the prognosis

    • Congress Reports
    • Gynecology
    • Oncology
    • Prevention and health care
    • RX
    • Studies
View Post
  • 8 min
  • Psoriasis treatment with biologics

What are the latest trends?

    • Congress Reports
    • Dermatology and venereology
    • Pharmacology and toxicology
    • Rheumatology
    • RX
    • Studies
View Post
  • 4 min
  • Flu vaccination for older people

Benefit of the high-dose influenza vaccine

    • Congress Reports
    • General Internal Medicine
    • Geriatrics
    • Infectiology
    • RX
    • Studies
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Pathomechanisms, secondary prevention and treatment options
  • 2
    Effect of heat on diabetes technology
  • 3
    Improved quality of care aims for satisfied patients
  • 4
    Dr. ChatGPT: Large language models in everyday clinical practice
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.